Miao-Lin Hu

Inhibition of proliferation of a hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional intercellular communication

Fucoxanthin is one of the most abundant carotenoids found in Undaria pinnatifida and has been shown to inhibit tumor proliferation in vitro. However, the mechanisms underlying the anti-cancer effects of fucoxanthin are unclear. In this study, we hypothesized that fucoxanthin may cause cell cycle arrest and enhance gap junctional intercellular communication (GJIC) in SK-Hep-1 human hepatoma cells. Data revealed that fucoxanthin (1-20microM) strongly and concentration-dependently inhibited the proliferation of SK-Hep-1 cells at 24h of incubation, whereas fucoxanthin facilitated the growth of a murine embryonic hepatic (BNL CL.2) cells at 24h of incubation and only slightly slowed the cell proliferation at 48h. In SK-Hep-1 cells, fucoxanthin caused cell cycle arrest at G0/G1 phase and induced cell apoptosis, as evidenced by increased subG1 cells and induction of DNA strand breaks. Using scrape loading-dye-transfer assay, fucoxanthin was found to significantly enhance GJIC of SK-Hep-1 cells without affecting that of BNL CL.2 cells. In addition, fucoxanthin significantly increased protein and mRNA expressions of connexin 43 (Cx43) and connexin 32 (Cx32) in SK-Hep-1 cells. Moreover, fucoxanthin markedly increased the concentration of intracellular calcium levels in SK-Hep-1 cells. Thus, fucoxanthin is specifically antiproliferative against SK-Hep-1 cells, and the effect is associated with upregulation of Cx32 and Cx43, which enhances GJIC of SK-Hep-1 cells. The enhanced GJIC may be responsible for the increase of the intracellular calcium level, which then causes cell cycle arrest and apoptosis.

The antioxidant and prooxidant activity of some B vitamins and vitamin-like compounds

The antioxidant and prooxidant properties of some B vitamins (BVIT) and vitamin-like compounds (VLC) that are commonly included in multivitamin preparations were investigated. Microsomal lipid peroxidation induced by FeCl3 and ascorbate was dose-dependently inhibited by pyridoxal and pantothenate but was stimulated by thiamin, pyridoxine and carnitine. Among the compounds tested, only pyridoxine and pyridoxal reacted, but rather poorly, with superoxide anions. All test compounds reacted with .OH with second-order rate constants comparable or higher than that for mannitol, as assayed using deoxyribose oxidation by a system containing EDTA-chelated Fe(III), H2O2 and ascorbate. When assayed in the absence of EDTA, pyridoxal showed increased inhibition of deoxyribose oxidation over that in the presence of EDTA, suggesting a potent ability of pyridoxal to bind and deactivate iron. Pantothenate, pyridoxine and myo-inositol appeared to equally inhibit deoxyribose oxidation both in the presence and absence of EDTA. The lack of inhibition on deoxyribose oxidation in the absence of EDTA by thiamin, carnitine and choline may suggest that the .OH-scavenging ability is equalled by the ability of the scavenger-iron complexes to form .OH or other redox active species. However, stimulation of lipid peroxidation by pyridoxine was unexplained and the effect was not attributed to reduction of Fe(III) to Fe(II). This study shows that the radical-scavenging ability of BVIT and VLC did not correlate with their effects on microsomal lipid peroxidation. Moreover, the stimulation of lipid peroxidation by thiamin, pyridoxine and carnitine suggests that supplementation of large amounts of these compounds may not be desirable.

Growth inhibitory efficacy of lycopene and β-carotene against androgen-independent prostate tumor cells xenografted in nude mice.

SCOPE In this study, we evaluated the efficacy of lycopene against the growth of prostate cancer in vivo. METHODS AND RESULTS Athymic nude mice were implanted subcutaneously with human androgen-independent prostate carcinoma PC-3 cells. They were supplemented with a low or a high dose of lycopene (4 and 16 mg/kg) and a single dose of β-carotene (16 mg/kg) twice a week for 7 wk. At the end of the experiment, both lycopene and β-carotene strongly inhibited the tumor growth, as evidenced by the decrease in tumor volume and tumor weight. High-dosage lycopene and β-carotene significantly decreased the expression of proliferating cell nuclear antigen in tumor tissues and increased the levels of insulin-like growth factor-binding protein-3 in plasma. In addition, high-dosage lycopene supplementation significantly decreased the vascular endothelial growth factor (VEGF) levels in plasma. In contrast, β-carotene supplementation significantly increased the VEGF levels, as compared with tumor control group. CONCLUSION Lycopene and β-carotene supplementation suppressed the growth of prostate tumor cells, and the effects are likely associated with reduction of proliferation (attenuation of proliferating cell nuclear antigen expression) and with interference of the insulin-like growth factor 1 signaling (increased plasma insulin-like growth factor-binding protein-3 levels). Furthermore, the inhibition of VEGF by lycopene suggests that the antitumor mechanisms of lycopene also involve anti-angiogenesis.

Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways

SCOPE Limited in vitro data show that lycopene may be anti-angiogenic but with unclear mechanisms. Here, we employed ex vivo and in vivo assays to substantiate the anti-angiogenic action of lycopene and determined its molecular mechanisms in human umbilical vein endothelial cells (HUVECs). METHODS AND RESULTS The anti-angiogenic activity of lycopene was confirmed by ex vivo rat aortic ring and in vivo chorioallantoic membrane assays. Furthermore, the in vivo matrigel plug assay in mice demonstrated that lycopene implanted s.c. at the highest dose used (400 μg/plug) completely inhibited the formation of vascular endothelial cells induced by vascular endothelial growth factor (VEGF). As expected, lycopene inhibited tube formation, invasion, and migration in HUVECs, and such actions were accompanied by reduced activities of matrix metalloproteinase-2, urokinase-type plasminogen activator, and protein expression of Rac1, and by enhancing protein expression of tissue inhibitors of metalloproteinase-2 and plasminogen activator inhibitor-1. Moreover, lycopene attenuated VEGF receptor-2 (VEGFR2)-mediated phosphorylation of extracellular signal-regulated kinase (ERK), p38, and Akt as well as protein expression of PI3K. CONCLUSION Our data demonstrate the anti-angiogenic effect of lycopene both in vitro and in vivo. The anti-angiogenic activity of lycopene may involve inhibition of MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways.

Trapping of Methylglyoxal by Curcumin in Cell-Free Systems and in Human Umbilical Vein Endothelial Cells

Curcumin, the most active compound of curcuminoids, has been shown to inhibit formation of advanced glycation end products (AGEs) in streptozotocin-induced diabetic rats. However, little is known on whether curcumin may trap methylglyoxal (MGO), a major reactive dicarbonyl compound, to inhibit AGE formation. We found that one molecule of curcumin effectively trapped one molecule of MGO at a 1:3 ratio at 24 h of incubation under physiological conditions (pH 7.4, 37 °C). Curcumin decreased N(ε)-(carboxymethyl)lysine (CML) expression in human umbilical vein endothelial cells. We further used two curcumin analogues, dimethoxycurcumin (DIMC) and ferulic acid, to investigate the possible MGO-trapping mechanism of curcumin. Results reveal that DIMC, but not ferulic acid, exhibited MGO-trapping capacity, indicating curcumin traps MGO at the electron-dense carbon atom (C10) between the two keto carbon groups. Thus, curcumin may prevent MGO-induced endothelial dysfunction by directly trapping MGO.

L-Carnosine Inhibits Metastasis of SK-Hep-1 Cells by Inhibition of Matrix Metaoproteinase-9 Expression and Induction of an Antimetastatic Gene, nm23-H1

Antioxidants have been suggested to inhibit the expression of matrix metalloproteinases (MMPs), especially MMP-9, which plays a critical role in tumor metastasis. Because of its antioxidant activity and the ability to chelate divalent cations, L-carnosine (LC) was tested for inhibition of MMP-9 in a highly invasive hepatocarcinoma, SK-Hep-1 cells. We found that LC (50–1,000 μ M) did not directly inhibit the activity of MMP-9 in a cell-free system. However, LC significantly inhibited the expression and activity of MMP-9 protein in SK-Hep-1 cells [inhibitory concentration of 50% (IC 50 )| = 105 and 63 μ M, respectively). Whereas LC did not inhibit the viability of SK-Hep-1 cells at concentrations up to 1,000 μ M within 3 days of incubation, this dipeptide significantly inhibited cell migration (IC 50 = 82 μ M) and invasion (IC 50 = 113 μM). LC significantly (P < 0.05) and dose dependently enhanced the expression of an antimetastatic gene, nonmetastatic cells 1, protein (nm23)-H1, at both protein and messenger ribonucleic acid (mRNA) levels. MMP-9 activity inversely correlated significantly with the expression of protein (r 2 = 0.77, P < 0.001) and mRNA (r 2 = 0.65, P < 0.001) of nm23-H1 in LC-treated cells. Thus, LC can inhibit the migration and invasion of SK-Hep-1 cells, and the effect is likely associated with upregulation of nm23-H1 and downregulation of MMP-9 expression.

Antimetastatic Effects and Mechanisms of Apo-8′-Lycopenal, an Enzymatic Metabolite of Lycopene, Against Human Hepatocarcinoma SK-Hep-1 Cells

Lycopene is primarily metabolized by carotenoid monoxygenase II into apo-8′- and apo-12′-lycopenal in the rat liver. Although lycopene possesses antimetastatic activity in a highly invasive hepatoma SK-Hep-1 cell line, little is known whether its metabolites have a similar effect. In this study, we investigated the antimetastatic effects of apo-8′-lycopenal (1–10 μM) in comparison with lycopene (10 μM) in SK-Hep-1 cells. We found that both apo-8′-lycopenal and lycopene inhibited the invasion and migration of SK-Hep-1 cells, and the effect of apo-8′-lycopenal was stronger than that of lycopene at the same concentration (10 μM). Mechanistically, apo-8′-lycopenal: 1) decreased the activities and protein expression of metalloproteinase-2 (MMP-2) and −9; 2) increased the protein expression of nm23-H1 and the tissue inhibitor of MMP (TIMP)-1 and −2; 3) suppressed protein expression of Rho small GTPases; and 4) inhibited focal adhesion kinase-mediated signaling pathway, such as ERK/p38 and PI3K-Akt axis. Overall, these results demonstrate that apo-8′-lycopenal possesses antimetastatic activity in SK-Hep-1 cells and that this effect is stronger than that of lycopene, suggesting that the antimetastatic effect may be attributed, at least in part, to its metabolites such as apo-8′-lycopenal.

Inhibitory Effect of Vitamin C in Combination With Vitamin K3 on Tumor Growth and Metastasis of Lewis Lung Carcinoma Xenografted in C57BL/6 Mice

Vitamin C in combination with vitamin K3 (vit CK3) has been shown to inhibit tumor growth and lung metastasis in vivo, but the mechanism of action is poorly understood. Herein, C57BL/6 mice were implanted (s.c.) with Lewis lung carcinoma (LLC) for 9 days before injection (i.p.) with low-dose (100 mg vit C/kg + 1 mg vit K3/kg), high-dose (1,000 mg vit C/kg + 10 mg vit K3/kg) vit CK3 twice a week for an additional 28 days. As expected, vit CK3 or cisplatin (6 mg/kg, as a positive control) significantly and dose-dependently inhibited tumor growth and lung metastasis in LLC-bearing mice. Vit CK3 restored the body weight of tumor-bearing mice to the level of tumor-free mice. Vit CK3 significantly decreased activities of plasma metalloproteinase (MMP)-2, -9, and urokinase plasminogen activator (uPA). In lung tissues, vit CK3 1) increased protein expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, nonmetastatic protein 23 homolog 1 and plasminogen activator inhibitor-1; 2) reduced protein expression of MMP-2 and MMP-9; and 3) inhibited the proliferating cell nuclear antigen (PCNA). These results demonstrate that vit CK3 inhibits primary tumor growth and exhibits antimetastastic potential in vivo through attenuated tumor invasion and proliferation.

Effects of Lycopene Supplementation on Plasma and Tissue Lycopene Levels in Various Rodent Strains

Lycopene has been shown to have various biologic effects, and rats and mice are often used for elucidating its in vivo effects and mechanisms. Here, we compared plasma and tissue lycopene levels in F344 rats, BALB/c mice, nude mice, and gerbils by oral supplementation with lycopene (20 mg/kg BW x 2d) every other morning for 10 days. We found that livers accumulated substantially more lycopene than kidneys and that the hepatic lycopene contents varied greatly in these animals, with gerbils being most efficient (1432 +/- 235 nmol/g), followed by nude mice (524 +/- 133 nmol/g), F344 rats (28 +/- 11 nmol/g), and BALB/c mice (5 +/- 2 nmol/g). Plasma lycopene concentrations also varied greatly, of which the highest was found in gerbils (667 +/- 160 nmol/L), followed by nude mice (224 +/- 51 nmol/L), then by BALB/c mice and F344 rats (198 +/- 52 and 139 +/- 41 nmol/L, respectively). Interestingly, plasma and tissue beta-carotene concentrations in these animals were markedly decreased by lycopene supplementation. To determine the steady-state levels of plasma lycopene, we fed 10 gerbils with lycopene (20 mg/kg BW x 2d) for 20 days, and we found a steady-state level of plasma lycopene between 597 to 722 nmol/L. Our results demonstrate that gerbils and nude mice are better accumulators than F344 rats and BALB/c mice, and that the former species may be more useful for studying the in vivo effects of lycopene.

Anti-angiogenic effects of lycopene through immunomodualtion of cytokine secretion in human peripheral blood mononuclear cells.

The carotenoid lycopene has been reported to possess anti-metastatic activity which may be associated with immunomodulation. However, the anti-angiogenic effects and mechanisms of action of lycopene have not been reported. In this study, we investigated the immunomodulatory effect on in vitro and ex vivo angiogenesis of lycopene. We found that the proliferation, migration and the matrigel tube formation of human umbilical vein endothelial cells (HUVECs) was remarkably inhibited by conditioned medium (CM) of human peripheral blood mononuclear cells (MNC-CM) stimulated with various dose (1-10 μmol/L) of lycopene (LP-MNC-CM). LP-MNC-CM treatment inhibited ex vivo angiogenesis, as revealed by chicken egg chorioallantoic membrane assay. We further examined the effects of lycopene stimulation on cytokine levels in MNC and showed that, as compared to the control, lycopene (10 μmol/L) significantly (P<.001) up-regulated interleukin (IL)-12 by 163% and interferon (IFN)-γ by 531%. Furthermore, pre-treatment of HUVECs with dexamethasone, an IL-12 inhibitor, blocked the anti-angiogenic effects of LP-MNC-CM in parallel with inhibition of IL-12 and IFN-γ induction in MNC. These results demonstrate that lycopene has a potent anti-angiogenic effect and that these effect may be associated with its up-regulation of IL-12 and IFN-γ.